Global Bispecific Antibody Therapeutics Market, 2017-2030 - Overall Pipeline Comprises of 200+ Molecules

News provided by

11 Oct, 2017, 18:30 BST

DUBLIN, October 11, 2017 /PRNewswire/ --

The "Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030" report has been added to Research and Markets' offering.

The Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030' report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an elaborate discussion on the future potential of this upcoming market.

The field has captured the interest of several drug developers, including both small and large companies. As indicated before, the applicability of these engineered biomolecules is vast. Presently, only one bispecific antibody, BLINCYTO (2014), is available for therapeutic use. However, the development pipeline of bispecific antibody based drugs has several promising candidates that are likely to result in commercial success stories in the foreseen future.

The overall pipeline comprises of over 200 molecules that are under development for the treatment of various disease indications across different therapeutic areas, including oncology, autoimmune disorders and infectious diseases. Of these, more than 60 molecules are currently under clinical evaluation, while over 140 product candidates are in the discovery / preclinical stages.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2017-2030.

The research, analysis and insights presented in this report include potential sales of bispecific antibody therapeutics that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel bispecific antibody therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Jane Dancer (CBO, F-star), Ludge Groe-Hovest (Founder and CSO, Synimmune), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Bispecific Antibody Therapeutics: Technology Platforms

6. Drug Profiles

7. Market Forecast And Opportunity Analysis

8. Partnerships And Collaborations

9. Key Insights

10. Case Study: Life Cycle Management Strategies

11. Case Study: Promotional/Marketing Strategies

12. SWOT Analysis

13. Conclusion

14. Interview Transcripts

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organizations

Companies Mentioned

Abbott
AbbVie
AbCheck
AbClon
Ablynx
AbMed (a subsidiary of Abpro)
Abpro
Abzena
Adimab
Aduro Biotech
Advagene Biopharma
Advaxis Immunotherapies
Affimed
Agenus
Ajou University, South Korea
Albert Einstein College of Medicine, US
Alexo Therapeutics
Alissa Pharma
Alligator Bioscience
Alnylam Pharmaceuticals
Ambrx
Amgen
Amphivena Therapeutics
AnaptysBio
AP Biosciences
Aptevo Therapeutics
ARIAD Pharmaceuticals
Arrowhead Pharmaceuticals
AstraZeneca
Atlante Biotech
Avillion
Balgrist University Hospital, Switzerland
Baliopharm (acquired by Alvotech)
Barbara Ann Karmanos Cancer Institute, US
Baxalta
Bayer
Benhealth Biopharmaceutical
Beth Israel Deaconess Medical Center, US
BIOCAD
Biocells (Beijing) Biotech
Biogen
BioInvent International
BioLineRx
BIOMUNEX Pharmaceuticals
BioNovion (acquired by Aduro Biotech)
BioNTech
Biotecnol
Bioverativ
Boehringer Ingelheim
California Institute for Biomedical Research, US
Catalent Biologics
Celgene
Cepheid
ChemPartner
Chugai Pharmaceutical
CMC Biologics
Columbia University, US
Cormorant Pharmaceuticals (acquired by Bristol-Myers Squibb)
Covagen (acquired by Cilag)
Creative Biolabs
CytomX Therapeutics
Daiichi Sankyo
Denali Therapeutics
Duke Neurosurgery, US
Dutalys
Eddingpharm
Eli Lilly
Emergent BioSolutions
EnGeneIC
EngMab (acquired by Celgene)
EpimAb Biotherapeutics
Fabion Pharmaceuticals
Fidelity Management & Research
Five Prime Therapeutics
Flatiron Health
Foundation Medicine
Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Germany
Fresenius Biotech
F-star
Fudan University, China
Fusion Antibodies
FZata
Ganymed Pharmaceuticals (acquired by Astellas Pharma)
Genentech
General Electric (GE)
Genmab
Genzyme
German Cancer Research Center (DKFZ), Germany
Gilead Sciences
Glaxo Smith Kline (GSK)
Glenmark Pharmaceuticals
Goodwin Biotechnology
Guangdong Medical University, China
Gustave Roussy
Hanmi Pharmaceutical
Hanwha Chemical R&D Center, Korea
Harvard University, US
Henlix Biotech
Humabs BioMed
Human Longevity
i2 Pharmaceuticals
IGM Biosciences
Immatics Biotechnologies
Immune Pharmaceuticals
Immunomedics
Imunexus
Incyte
InflaRx
Innate Pharma
Innovent Biologics
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland
Institute for Research in Biomedicine (IRB) Barcelona, Spain
Intarcia Therapeutics
Ipsen
Janssen Biotech
Janssen-Cilag
JW Pharmaceutical
Kairos Therapeutics
Kymab
Kyowa Hakko Kirin
Leica Biosystems
Leland Stanford Junior University, US
Leukemia and Lymphoma Society, US
Ligand Pharmaceuticals
LINDIS Biotech
MacroGenics
Masonic Cancer Center, US
Massachusetts General Hospital, US
Massachusetts Institute of Technology (MIT), US
MediaPharma
MedImmune
Memorial Sloan Kettering Cancer Center, US
Merck
Merrimack Pharmaceuticals
Merus
Micromet
Mitsubishi Tanabe Pharma
MorphoSys
Nanjing Abingen
Nanjing Medical University, China
National Cancer Institute (NCI), US
Neovii Biotech
Northeast Agricultural University, China
Novartis
Novimmune
Novo Nordisk
Numab
OcellO
OncoMed Pharmaceuticals
Ono Pharmaceutical
Oxis Biotech
Pfizer
PharmAbcine
Pharmacyclics
Pieris Pharmaceuticals
Regeneron Pharmaceuticals
RenMin Hospital, Wuhan University, China
Roche
Samsung Advanced Institute of Technology (SAIT), South Korea
Sanofi
SATT Sud-Est
SBI Pharmaceuticals
Sea Lane Biotechnologies
Second Military Medical University, Shanghai
Selexis
Servier
Shire
SiteOne Therapeutics
Spectrum Pharmaceuticals
Stanford University, US
Stemcentrx
Sun Yat-sen University, China
Sutro Biopharma
Synergys
Synimmune
Systimmune
Taisho Pharmaceutical
Takeda Pharmaceutical
Teijin Pharma
TESARO
The Scripps Research Institute, US
The University of Texas MD Anderson Cancer Center, US
Tianjin Nankai Hospital, China
TriOn Pharma
University of California, Los Angeles (UCLA), US
University of Cologne, Germany
University of Groningen, Netherlands
University of Minnesota, US
University of Munich, Germany
University of Virginia, US
Van Herk Investments
Vanderbilt Vaccine Center, US
Vrije Universiteit Brussel, Belgium
Wal-Mart
Warburg Pincus
Wellcome Trust Sanger Institute, England
Wuhan YZY Biopharma
WuXi Biologics
Xencor
Y-mAbs Therapeutics
Zhejiang Hisun Pharmaceutical
Zymeworks
Zyngenia

For more information about this report visit https://www.researchandmarkets.com/research/664rwb/bispecific

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Global Bispecific Antibody Therapeutics Market, 2017-2030 - Overall Pipeline Comprises of 200+ Molecules

Related Links

Contact PR Newswire

Products

About

My Services